{"entity":{"id":"nct03635021","kind":"trial","name":"Study to Evaluate the Efficacy of FOLFOX + Panitumumab Followed by FOLFIRI + Bevacizumab (Sequence 1) Versus FOLFOX + Bevacizumab Followed by FOLFIRI + Panitumu","aka":["CR-SEQUENCE"],"tldr":"A phase 3 trial of panitumumab and bevacizumab (glioblastoma use) in colorectal cancer, run by Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD), active but no longer recruiting.","summary":"Study to Evaluate the Efficacy of FOLFOX + Panitumumab Followed by FOLFIRI + Bevacizumab (Sequence 1) Versus FOLFOX + Bevacizumab Followed by FOLFIRI + Panitumumab (Sequence 2) in Untreated Patients With Wild-type RAS Metastatic, Primary Left-sided, Unresectable Colorectal Cancer is a phase 3, randomised interventional study registered as NCT03635021 by Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD), with a registry enrolment figure of 419 participants, started 2018-10-15 and due to reach its primary completion in 2025-06-28. Interventions recorded: FOLFOX regimen; Panitumumab; Bevacizumab; FOLFIRI regimen. Conditions listed: Colorectal Cancer. Primary outcome: Progression-free survival rate at 35 months. Colorectal eligibility wording from the registry: \"Histologically confirmed adenocarcinoma of the left colon or rectum (originate in the splenic flexure, descending colon, sigmoid colon, or rectum) in patients with unresectable (not amenable to radical surgery of metastases at the study inclusion) metastatic (M1) disease\". Sites: Spain. No results are recorded here; the registry entry is the source.","status":"active","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT03635021","url":"https://clinicaltrials.gov/study/NCT03635021"}],"tags":["ctgov-ingest","colorectal-deep-dive"],"related":[],"cancers":["rectal-cancer","colon-cancer"],"sections":[],"technologies":["monoclonal-antibody"],"targets":[],"drugs":["panitumumab","bevacizumab-glioma"],"companies":["amgen"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT03635021","phase":"3","setting":"Phase III Randomized Sequential Open-label Study to Evaluate the Efficacy of FOLFOX + Panitumumab Followed by FOLFIRI + Bevacizumab (Sequence 1) Versus FOLFOX + Bevacizumab Followed by FOLFIRI + Panitumumab (Sequence 2) in Untreated Patients With Wild-type RAS Metastatic, Primary Left-sided, Unresectable Colorectal Cancer: The CR-SEQUENCE","sponsor":"Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)","enrolled":419,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct03635021/","neighbours":{"cancer":[{"id":"colon-cancer","kind":"cancer","name":"Colon cancer (adenocarcinoma of the colon)","route":"/cancers/colon-cancer/"},{"id":"rectal-cancer","kind":"cancer","name":"Rectal cancer","route":"/cancers/rectal-cancer/"}],"technology":[{"id":"monoclonal-antibody","kind":"technology","name":"Monoclonal antibodies","route":"/technologies/monoclonal-antibody/"}],"drug":[{"id":"bevacizumab-glioma","kind":"drug","name":"Bevacizumab (glioblastoma use)","route":"/drugs/bevacizumab-glioma/"},{"id":"panitumumab","kind":"drug","name":"Panitumumab","route":"/drugs/panitumumab/"}],"company":[{"id":"amgen","kind":"company","name":"Amgen","route":"/companies/amgen/"}],"term":[{"id":"colorectal-trials-open-today","kind":"term","name":"Colorectal cancer trials open today (registry snapshot)","route":"/terms/colorectal-trials-open-today/"}]}}